KORU Medical Systems to Ring Nasdaq Closing Bell on February 12, 2020
February 10 2020 - 4:15PM
Business Wire
Repro Med Systems, Inc. dba KORU Medical Systems
(NASDAQ:KRMD) (“KORU Medical” or the “Company”) today announced
that Don Pettigrew, President & CEO, will ring the Nasdaq
Closing Bell on Wednesday, February 12, 2020 at 4:00 pm ET.
“We are honored to ring the closing bell in celebration of our
recent uplisting to Nasdaq, our corporate re-branding to KORU
Medical Systems, and our position as a market leader of innovative
and easy-to-use specialty infusion devices,” said Mr. Pettigrew.
“We appreciate the support of our customers, industry partners,
shareholders, employees, and board members, and remain focused on
providing new life and new beginnings to patients around the world
who use KORU Medical’s integrated Freedom Syringe Infusion System.
We continue to look forward to our future with confidence.”
About KORU Medical Systems KORU
Medical Systems develops, manufactures and commercializes
innovative and easy-to-use specialty infusion solutions that
improve quality of life for patients around the world. The FREEDOM
Syringe Infusion System currently includes the FREEDOM60® and
FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™
and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are
used for infusions administered in the home and alternate care
settings. For more information, please visit
www.korumedical.com.
Forward-Looking Statements
The statements contained herein include prospects, statements of
future expectations and other forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that are based on management's current views and assumptions and
involve known and unknown risks and uncertainties. Actual results,
performance or events may differ materially from those expressed or
implied in such forward-looking statements. Important factors that
could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: introduction of competitive
products; availability of insurance reimbursement; changes in U.S.
Food and Drug Administration regulations; changes to health care
policies; success of our research and development efforts; our
ability to raise capital if or when needed; acceptance of and
demand for new and existing products; expanded market acceptance of
the FREEDOM Syringe Infusion System; our ability to obtain required
governmental approvals; success in enforcing and obtaining patents;
continued performance by principal suppliers; continued customer
preference to work through distributors; continued service of key
personnel and attracting and maintaining new personnel; the costs,
duration and ultimate outcome of litigation; and general economic
and business conditions. These and other risks are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K, which filings are
available from the SEC and the Company’s website. The Company
undertakes no obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200210005690/en/
The Equity Group Inc. Devin Sullivan Senior Vice
President 212-836-9608 dsullivan@equityny.com
Kalle Ahl, CFA Vice President 212-836-9614 kahl@equityny.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024